Title:
COMPOUNDS AND METHODS FOR INHIBITING ALPHA-1 BETA-1 INTEGRINS
Document Type and Number:
WIPO Patent Application WO2002022571
Kind Code:
A3
Abstract:
Obtustatin is a novel, RGD-independent short disintegrin that potently and selectively inhibits the binding of alpha 1 beta 1 integrin to its adhesive ligand. Obtustatin, and fragments, derivatives, homologs and analogs of obtustatin may be used to treat diseases and modulate biological conditions associated with alpha 1 beta 1 integrin.
Inventors:
MARCINKIEWICZ CEZARY (US)
Application Number:
PCT/US2001/028522
Publication Date:
June 20, 2002
Filing Date:
September 12, 2001
Export Citation:
Assignee:
UNIV TEMPLE (US)
MARCINKIEWICZ CEZARY (US)
MARCINKIEWICZ CEZARY (US)
International Classes:
A61P7/12; A61P9/10; A61P21/04; C07K5/06; C07K5/068; C07K5/097; C07K5/103; C07K14/46; A61K38/00; (IPC1-7): A61K38/04; A61K38/05; A61K38/06; A61K38/07; A61K38/08; A61K38/09; A61K38/10; A61K38/16; A61K38/17; C07K5/04; C07K5/06; C07K5/08; C07K5/10; C07K7/04; C07K7/06; C07K14/46; G01N33/566; G01N33/567
Other References:
DATABASE HCAPLUS [online] CHEMICAL ABSTRACTS SERVICE (COLUMBUS, OHIO, USA); FOLSCH G. ET AL.: "Hydrolysis of phosphopeptides. II. Leucine aminopeptidase hydrolysis of free and O-phosphorylated serine peptides", XP002909243, accession no. STN Database accession no. 1966:28765
See also references of EP 1322322A4
See also references of EP 1322322A4
Download PDF: